| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
Roxatidine acetate is a specific and competitive H2 receptor antagonist. It is currently approved in South Africa under the tradename Roxit. |
| Indication |
For the treatment of disorders of the upper gastro-intestinal region that are due to an excess of hydrochloric acid in the gastric juice, i.e. duodenal ulcers, benign gastric ulcers. Also for prophylaxis of recurrent gastric and duodenal ulcers |
| Pharmacology |
Roxatidine acetate suppresses the effect of histamine on the parietal cells of the stomach (H2-receptor antagonist). This suppressive action is dose-dependent. As a result, the production and secretion, particularly of gastric acid, are reduced. Roxatidine acetate has no antiandrogenic effects and does not influence drug-metabolizing enzymes in the liver. |
| Toxicity |
Oral, mouse LD50: 1000 mg/kg |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Roxatidine acetate is rapidly metabolised to the primary, active desacetyl metabolite. |
| Absorption |
Well absorbed orally (80–90% bioavailability). |
| Half Life |
5-6 hours |
| Protein Binding |
5-7% |
| References |
|
| External Links |
|